Treatment of glioma cells with the catalytic LSD1 inhibitors tranylcypromine (TCP) or GSK LSD1 was able to increase MICB and ULBP4 expression, enhancing human NK-cell mediated lysis of the target cells (137). Here, KDM1A is linked to central nervous system cancer.